Where Trastuzumab Deruxtecan Fits — in Your Treatment Plan

For HER2-positive breast cancer, the evidence base for first-line treatment — built over many years in large trials — established a combination of trastuzumab, pertuzumab, and chemotherapy as the standard starting point. Trastuzumab deruxtecan was studied and approved after this regimen, which is why guidelines place it there. In HER2-low disease, the pivotal trials enrolled patients who had already received prior chemotherapy, so the approval reflects where the benefit was demonstrated. Drug approval follows the evidence — the position in the sequence is tied to where the clinical trials were designed to look, not where the drug could not in principle work.

Not exactly. DXd is a potent topoisomerase I inhibitor similar in class to drugs used in some conventional chemotherapy regimens, but it is more potent and is delivered differently. Because it is mostly released inside HER2-carrying cancer cells rather than circulating freely through the blood, some side effects differ from what you may have experienced before. Hair loss still occurs. Nausea is common. But the specific pattern — what you feel and when — may not match your prior experience with other chemotherapy. It is worth describing your history with chemotherapy side effects to your team so they can tell you what to expect from this one.

Outside of clinical trials, trastuzumab deruxtecan is generally used as a single agent — not in combination with other targeted drugs or immunotherapy at the same time. The evidence for its benefit comes from trials where it was given alone. Combining it with another agent can multiply side effects in ways that are not always outweighed by additional benefit. If a clinical trial testing a combination approach is available and suitable for you, your team may raise that option — but it would be in a trial setting, not as standard care.

When DXd is released inside a cancer cell, a portion of it can pass through the cell wall and enter nearby cells — including cells that do not themselves carry HER2. This is called the bystander effect. It is one reason trastuzumab deruxtecan has shown activity in HER2-low disease, where not every cancer cell carries the same amount of HER2. The drug can reach and damage cells that the antibody could not have targeted directly. Whether this affects your individual response is something your team cannot predict with certainty in advance — it is an active area of ongoing research.

This is a reasonable question to raise before you start, so you understand the full plan rather than facing it under pressure later. Options vary by cancer type, by what you have already received, and by your overall condition at the time. For breast cancer, NCCN and ESMO guidance lists several options at this point, including other HER2-directed agents and cytotoxic chemotherapy. Ask your oncologist what the next step would likely be and what would need to be true for that decision to be made. Knowing the plan in advance is not pessimism — it is preparation.

No, it differs by cancer type. Trastuzumab deruxtecan is also approved for HER2-mutant non-small cell lung cancer and HER2-positive gastric or gastro-oesophageal cancer, and the sequencing differs for each. In lung cancer, it is used after prior treatment; in gastric cancer, it follows first-line chemotherapy. If you are being treated for a cancer other than breast cancer, what you read on breast cancer pages may not describe your situation. Ask your oncologist specifically about the evidence for your tumour type and where this drug fits within that sequence.